Zenrelia Tablets

Zenrelia™ Tablets

Zenrelia™ is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs.

Dogs (at least 12 months old, weighing 6.7 lbs or more)

Ilunocitinib

Zenrelia™ 

Janus Kinase (JAK) Inhibitor, Antipuritic, Immunomodulator

Elanco

Zenrelia™ 4.8 mg Tablets: 11 mm, yellow, oval tablet, scored in half, no imprint. (NDC 58198-5536-01, 58198-5536-03)

Zenrelia™ 6.4 mg Tablets: 12 mm, yellow, oval tablet, scored in half, no imprint. (NDC 58198-5537-01, 58198-5537-03)

Zenrelia™ 8.5 mg Tablets: 13 mm, yellow, oval tablet, scored in half, no imprint. (NDC 58198-5538-01, 58198-5538-03)

Zenrelia™ 15 mg Tablets: 16 mm, yellow, oval tablet, scored in half, no imprint. (NDC 58198-5539-01, 58198-5539-03)

Ilunocitinib

Zenrelia™ should be given orally as directed by your veterinarian. Zenrelia™ may be administered with or without food. Wash hands immediately after handling tablets. 

Give the dose as soon as possible. If it is almost time for the next dose, skip the missed dose, and continue with the regular schedule. Do not give 2 doses at once.

Side effects may include diarrhea, vomiting, anorexia, polydipsia, dermal lumps, elevated liver enzymes, dermatitis, or lethargy. Notify your veterinarian if side effects appear and remain troublesome. Other side effects may occur, if you notice anything unusual, contact your veterinarian.

The following drugs can potentially interact with ilunocitinib: cyclosporine, glucocorticoids, and other immunosuppresive agents. Contact your veterinarian if your pet experiences any unusual reactions when different medications are given together.

Make sure to tell your veterinarian what other medication or supplements you are giving to your pet. Quite often your veterinarian may prescribe two different medications, even if a drug interaction may occur. In this case, your veterinarian may vary the dose and/or monitor your pet more closely.

Zenrelia™ has not been evaluated in breeding, pregnant, or lactating dogs.

Do not use on dogs less than 12 months of age or dogs with serious infections. Discontinue Zenrelia™ for at least 28 days to 3 months prior to vaccination and withhold Zenrelia™ for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia™. The use of Zenrelia™ has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. Zenrelia™ may increase susceptibility to infection, including demodicosis, and exacerbate neoplastic conditions. Dogs receiving Zenrelia™ should be monitored for the development of infections, including demodicosis, and neoplasia. If dog shows signs of infection, difficulty breathing or is listless, or has a fever, contact your veterinarian immediately.  If you see abnormal skin changes or growths, contact your veterinarian. 

Allergic reactions to medications may occur. Be sure to inform Vetsource and your veterinarian if your pet has any known drug sensitivities or allergies. If your pet displays symptoms of an allergic reaction, call your veterinarian immediately or go to a veterinary emergency clinic. Symptoms may include but are not limited to: swollen lips, tongue, face, airways; difficulty breathing; agitation; profuse salivation; vomiting; widespread hives and itching.

If you are concerned that your pet has experienced an adverse reaction to this medication, please contact the manufacturer Elanco at 888-545-5973 or Vetsource customer service at 877-738-4443.

Store at 59°F to 77°F in controlled room temperature, excursions permitted between 41° to 104°F. Keep this medicine out of reach of children. Store in a childproof container. Store this medicine in a cool, dry place at room temperature. Store away from heat and direct sunlight. Do not store this medicine in the bathroom, near the kitchen sink or in damp places. The medicine may break down if exposed to heat or moisture.